Loading organizations...
§ Private Profile · 161 Cheshire Lane Suite 100, Minneapolis, MN 55441-5433
SuperDimension is a technology company.
SuperDimension develops and commercializes advanced medical devices for minimally invasive pulmonology, primarily known for its superDimension Navigation System. This system employs electromagnetic navigation bronchoscopy (ENB) to facilitate precise, real-time 3D navigation within the tracheobronchial tree, enabling physicians to access and diagnose peripheral lung nodules that are difficult to reach with conventional methods. Its core capability lies in improving visualization and accessibility for lung health procedures.
The company was founded in 1995 by Pinchas Gilboa, stemming from the critical insight that accurately reaching and sampling lesions in the challenging peripheral regions of the lung was essential for early and effective diagnosis. Gilboa’s expertise in medical technology provided the foundation for innovating sophisticated navigation tools to address this significant unmet clinical need.
SuperDimension’s products are utilized by pulmonologists and thoracic surgeons globally, aiding them in the accurate biopsy and diagnosis of suspicious lung lesions. The company's enduring vision, now integrated into Medtronic’s Lung Health offerings, is to enhance the diagnosis and management of lung diseases by delivering technologies that provide superior precision and efficiency, thereby working towards earlier detection and improved patient outcomes.
SuperDimension has raised $50.0M across 3 funding rounds.
SuperDimension has raised $50.0M in total across 3 funding rounds.
SuperDimension has raised $50.0M across 3 funding rounds. Most recently, it raised $10.0M Series U in September 2010.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Sep 1, 2010 | $10M Series U | — | Pitango Venture Capital | Announced |
| Jun 1, 2005 | $27M Series B | — | OrbiMed | Announced |
| Jan 1, 2003 | $13M Series U | — | Pitango Venture Capital | Announced |
SuperDimension has raised $50.0M in total across 3 funding rounds.
SuperDimension's investors include Pitango Venture Capital, OrbiMed.
superDimension was a medical device company founded in 1995 that developed and marketed minimally invasive pulmonology devices, primarily the i-Logic System (an evolution of the inReach system), for diagnosing and treating distal lung diseases, including early lung cancer detection.[1][2][5] The company served pulmonologists and thoracic physicians, addressing the challenge of accessing small, peripheral lung lesions beyond traditional bronchoscopy reach, targeting a market of over 8 million patients with tools like electromagnetic navigation bronchoscopy (ENB).[1][5] It raised $58.04M total, including a $24.8M debt-equity round, before being acquired by Covidien in March 2012 for $300M and later integrated into Medtronic.[1][3][4]
superDimension originated from an unexpected pivot: founder Pinhas Averbuch initially developed navigation technology for video games, akin to early Wii motion controls, before shifting to medical applications after leaving a prior venture, MediGuide.[1] Frustrated with electromagnetic limitations in existing systems, Averbuch innovated a sensor-guided approach using a magnetic field generator under the patient, eliminating bulky components for precise lung navigation.[1] Based in Minneapolis (with offices in Israel and Germany), the company gained early traction with its inReach ENB tool, debuting the second-generation i-Logic System in 2009 at major conferences like CHEST and ASTRO, alongside securing AMA Category I CPT codes for reimbursement starting 2010.[5][6]
superDimension rode the wave of minimally invasive diagnostics in pulmonology during the early 2000s, capitalizing on rising lung cancer incidence and limitations of conventional tools amid growing demand for precise, early intervention.[5][6] Its timing aligned with advances in electromagnetic navigation and 3D imaging, influencing the shift toward ENB as a standard for peripheral lung biopsies—now a cornerstone in thoracic oncology protocols.[1][5] By pioneering catheter-based, GPS-like systems, it shaped market forces favoring tech-enabled medtech, paving the way for integrations in giants like Covidien/Medtronic and spurring competitors like Axis Surgical in visualization tech.[1][3]
Post-2012 acquisition, superDimension's technology endures within Medtronic's ENB portfolio, evolving with AI-enhanced imaging and robotics for even broader lung intervention applications.[3] Trends like precision oncology, remote diagnostics, and value-based care will amplify its legacy, potentially expanding to therapeutic ablations or integrated AI navigation. Its influence grows indirectly through Medtronic's ecosystem dominance, underscoring how nimble medtech innovators disrupt via targeted navigation—echoing its game-to-lung pivot that unlocked $300M value.[1][3]